HRP20211198T1 - Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe - Google Patents
Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe Download PDFInfo
- Publication number
- HRP20211198T1 HRP20211198T1 HRP20211198TT HRP20211198T HRP20211198T1 HR P20211198 T1 HRP20211198 T1 HR P20211198T1 HR P20211198T T HRP20211198T T HR P20211198TT HR P20211198 T HRP20211198 T HR P20211198T HR P20211198 T1 HRP20211198 T1 HR P20211198T1
- Authority
- HR
- Croatia
- Prior art keywords
- modulators
- methods
- cystic fibrosis
- fibrosis transmembrane
- conductance regulator
- Prior art date
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 2
- FGVSFBNMCLIHJD-UHFFFAOYSA-N 1-(5-cyclopropyl-2-propan-2-yloxypyridin-3-yl)-N-(2-methylquinolin-5-yl)sulfonylcyclopropane-1-carboxamide Chemical group C1(CC1)C=1C=C(C(=NC=1)OC(C)C)C1(CC1)C(=O)NS(=O)(=O)C=1C=2C=CC(=NC=2C=CC=1)C FGVSFBNMCLIHJD-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Claims (2)
1. Spoj, naznačen time što je 1-{5-ciklopropil-2-[(propan-2-il)oksi]piridin-3-il}-N-(2-metilkinolin-5-sulfonil)ciklopropan-1-karboksamid, ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 1-{5-ciklopropil-2-[(propan-2-il)oksi]piridin-3-il}-N-(2-metilkinolin-5-sulfonil)ciklopropan-1-karboksamid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558430P | 2017-09-14 | 2017-09-14 | |
US201762608846P | 2017-12-21 | 2017-12-21 | |
EP20183402.5A EP3736270B1 (en) | 2017-09-14 | 2018-09-13 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211198T1 true HRP20211198T1 (hr) | 2021-10-29 |
Family
ID=63713961
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210099TT HRP20210099T1 (hr) | 2017-09-14 | 2021-01-20 | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe |
HRP20211198TT HRP20211198T1 (hr) | 2017-09-14 | 2021-07-26 | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe |
HRP20211200TT HRP20211200T1 (hr) | 2017-09-14 | 2021-07-26 | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210099TT HRP20210099T1 (hr) | 2017-09-14 | 2021-01-20 | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211200TT HRP20211200T1 (hr) | 2017-09-14 | 2021-07-26 | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe |
Country Status (33)
Country | Link |
---|---|
US (6) | US10988454B2 (hr) |
EP (4) | EP3736270B1 (hr) |
JP (4) | JP7064072B2 (hr) |
KR (1) | KR20200086661A (hr) |
CN (1) | CN111954664A (hr) |
AU (1) | AU2018332512A1 (hr) |
BR (1) | BR112020005102A2 (hr) |
CA (1) | CA3074945A1 (hr) |
CL (1) | CL2020000664A1 (hr) |
CO (1) | CO2020004249A2 (hr) |
CR (1) | CR20200157A (hr) |
CY (3) | CY1123761T1 (hr) |
DK (3) | DK3736267T3 (hr) |
EC (1) | ECSP20021913A (hr) |
ES (3) | ES2856751T3 (hr) |
HR (3) | HRP20210099T1 (hr) |
HU (3) | HUE052873T2 (hr) |
IL (1) | IL273163A (hr) |
LT (3) | LT3736270T (hr) |
MA (1) | MA50240B1 (hr) |
MD (3) | MD3681864T2 (hr) |
MX (1) | MX2020002806A (hr) |
PE (1) | PE20210140A1 (hr) |
PH (1) | PH12020500509A1 (hr) |
PL (3) | PL3736270T3 (hr) |
PT (3) | PT3736270T (hr) |
RS (3) | RS62185B1 (hr) |
RU (1) | RU2020113350A (hr) |
SG (1) | SG11202002101RA (hr) |
SI (3) | SI3736267T1 (hr) |
UA (1) | UA125541C2 (hr) |
WO (1) | WO2019053634A1 (hr) |
ZA (1) | ZA202002363B (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
EP3519401B1 (en) | 2016-09-30 | 2021-09-29 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
IL277491B (en) | 2016-12-09 | 2022-08-01 | Vertex Pharma | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
LT3697789T (lt) | 2017-10-18 | 2021-12-10 | Incyte Corporation | Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EP3897832B1 (en) * | 2018-12-18 | 2023-10-11 | Novartis AG | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives and their use in the treatment of a cftr mediated disease |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
US20220211692A1 (en) * | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
US20220213041A1 (en) * | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB602426A (en) * | 1945-10-24 | 1948-05-26 | Geigy Ag J R | Manufacture of aromatic acyl-sulphonamides |
MXPA03003174A (es) * | 2000-10-10 | 2003-07-14 | Smithkline Beecham Corp | Indoles substituidos, composiciones farmaceuticas que contienen dichos indoles y su uso como agentes de enlace ppar-y.. |
EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
AU2007351454B2 (en) | 2006-11-03 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
KR20100049667A (ko) * | 2007-08-29 | 2010-05-12 | 쉐링 코포레이션 | 바이러스 감염 치료용 2,3-치환된 인돌 유도체 |
CA2705586A1 (en) * | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-heterocyclic substituted indole derivatives and methods of use thereof |
CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
EP2231671B1 (en) | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20100134063A (ko) * | 2008-03-25 | 2010-12-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 낭포성 섬유증 막투과 전도성 조절자의 수용성 소분자 억제제 |
KR20110074916A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | N-(4-(7-아자비시클로[2.2.1]헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태 |
DK2365972T3 (en) * | 2008-11-06 | 2015-01-19 | Vertex Pharma | Modulators of atp-binding cassette conveyors |
EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN102458122A (zh) * | 2009-04-20 | 2012-05-16 | 人类健康研究所 | 含有哒嗪磺胺衍生物的化合物、组合物和方法 |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
ES2716723T3 (es) | 2011-09-20 | 2019-06-14 | Univ North Carolina Chapel Hill | Regulación de los canales de sodio por las proteínas PLUNC |
WO2014180562A1 (en) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
CN103484818A (zh) | 2013-09-25 | 2014-01-01 | 京东方科技集团股份有限公司 | 蒸镀方法、蒸镀装置和发光器件 |
CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
KR102132215B1 (ko) | 2014-04-03 | 2020-07-09 | 삼성전자주식회사 | 자기 터널 접합 구조물 형성 방법 및 이를 이용한 자기 메모리 소자의 제조 방법 |
CN112250627B (zh) * | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
SG11201703391VA (en) * | 2014-10-31 | 2017-05-30 | Abbvie S À R L | Substituted chromanes and method of use |
BR112017009194A2 (pt) | 2014-10-31 | 2017-12-26 | Abbvie Sarl | tetra-hidropiranos substituídos e método de uso |
JP2018516932A (ja) | 2015-06-02 | 2018-06-28 | アッヴィ・エス・ア・エール・エル | 置換ピリジンおよび使用方法 |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
EP3448842A1 (en) | 2016-04-26 | 2019-03-06 | AbbVie S.À.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
-
2018
- 2018-09-12 US US16/129,458 patent/US10988454B2/en active Active
- 2018-09-13 SI SI201830344T patent/SI3736267T1/sl unknown
- 2018-09-13 EP EP20183402.5A patent/EP3736270B1/en active Active
- 2018-09-13 MD MDE20200741T patent/MD3681864T2/ro unknown
- 2018-09-13 JP JP2020537292A patent/JP7064072B2/ja active Active
- 2018-09-13 EP EP18779798.0A patent/EP3681864B1/en active Active
- 2018-09-13 PL PL20183402T patent/PL3736270T3/pl unknown
- 2018-09-13 MD MDE20201160T patent/MD3736267T2/ro unknown
- 2018-09-13 KR KR1020207010867A patent/KR20200086661A/ko active IP Right Grant
- 2018-09-13 DK DK20183405.8T patent/DK3736267T3/da active
- 2018-09-13 HU HUE18779798A patent/HUE052873T2/hu unknown
- 2018-09-13 SI SI201830345T patent/SI3736270T1/sl unknown
- 2018-09-13 RS RS20210973A patent/RS62185B1/sr unknown
- 2018-09-13 CR CR20200157A patent/CR20200157A/es unknown
- 2018-09-13 ES ES18779798T patent/ES2856751T3/es active Active
- 2018-09-13 CA CA3074945A patent/CA3074945A1/en active Pending
- 2018-09-13 PL PL20183405T patent/PL3736267T3/pl unknown
- 2018-09-13 RU RU2020113350A patent/RU2020113350A/ru unknown
- 2018-09-13 WO PCT/IB2018/057020 patent/WO2019053634A1/en unknown
- 2018-09-13 LT LTEP20183402.5T patent/LT3736270T/lt unknown
- 2018-09-13 DK DK20183402.5T patent/DK3736270T3/da active
- 2018-09-13 LT LTEP18779798.0T patent/LT3681864T/lt unknown
- 2018-09-13 PL PL18779798T patent/PL3681864T3/pl unknown
- 2018-09-13 RS RS20210975A patent/RS62190B1/sr unknown
- 2018-09-13 HU HUE20183405A patent/HUE055050T2/hu unknown
- 2018-09-13 SI SI201830193T patent/SI3681864T1/sl unknown
- 2018-09-13 ES ES20183402T patent/ES2881881T3/es active Active
- 2018-09-13 UA UAA202002356A patent/UA125541C2/uk unknown
- 2018-09-13 HU HUE20183402A patent/HUE055241T2/hu unknown
- 2018-09-13 AU AU2018332512A patent/AU2018332512A1/en not_active Abandoned
- 2018-09-13 EP EP20183405.8A patent/EP3736267B1/en active Active
- 2018-09-13 RS RS20210082A patent/RS61899B1/sr unknown
- 2018-09-13 PT PT201834025T patent/PT3736270T/pt unknown
- 2018-09-13 MX MX2020002806A patent/MX2020002806A/es unknown
- 2018-09-13 DK DK18779798.0T patent/DK3681864T3/da active
- 2018-09-13 PT PT201834058T patent/PT3736267T/pt unknown
- 2018-09-13 PT PT187797980T patent/PT3681864T/pt unknown
- 2018-09-13 MD MDE20201159T patent/MD3736270T2/ro unknown
- 2018-09-13 CN CN201880073855.3A patent/CN111954664A/zh active Pending
- 2018-09-13 MA MA50240A patent/MA50240B1/fr unknown
- 2018-09-13 PE PE2020000670A patent/PE20210140A1/es unknown
- 2018-09-13 BR BR112020005102-0A patent/BR112020005102A2/pt not_active Application Discontinuation
- 2018-09-13 ES ES20183405T patent/ES2887449T3/es active Active
- 2018-09-13 SG SG11202002101RA patent/SG11202002101RA/en unknown
- 2018-09-13 EP EP21164249.1A patent/EP3865474A1/en not_active Withdrawn
- 2018-09-13 LT LTEP20183405.8T patent/LT3736267T/lt unknown
-
2020
- 2020-03-09 IL IL273163A patent/IL273163A/en unknown
- 2020-03-12 PH PH12020500509A patent/PH12020500509A1/en unknown
- 2020-03-13 CL CL2020000664A patent/CL2020000664A1/es unknown
- 2020-04-07 CO CONC2020/0004249A patent/CO2020004249A2/es unknown
- 2020-04-14 EC ECSENADI202021913A patent/ECSP20021913A/es unknown
- 2020-05-04 ZA ZA2020/02363A patent/ZA202002363B/en unknown
- 2020-05-19 US US16/878,430 patent/US10829473B2/en active Active
- 2020-05-19 US US16/878,416 patent/US10844041B2/en active Active
- 2020-05-19 US US16/878,468 patent/US10981890B2/en active Active
- 2020-05-19 US US16/878,421 patent/US10844042B2/en active Active
-
2021
- 2021-01-20 HR HRP20210099TT patent/HRP20210099T1/hr unknown
- 2021-01-28 CY CY20211100074T patent/CY1123761T1/el unknown
- 2021-04-15 US US17/231,482 patent/US20210238159A1/en not_active Abandoned
- 2021-07-26 HR HRP20211198TT patent/HRP20211198T1/hr unknown
- 2021-07-26 HR HRP20211200TT patent/HRP20211200T1/hr unknown
- 2021-08-03 CY CY20211100695T patent/CY1124615T1/el unknown
- 2021-08-04 CY CY20211100697T patent/CY1124401T1/el unknown
- 2021-09-27 JP JP2021156375A patent/JP7064073B2/ja active Active
- 2021-09-27 JP JP2021156376A patent/JP7064074B2/ja active Active
-
2022
- 2022-01-21 JP JP2022007648A patent/JP2022062093A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211198T1 (hr) | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe | |
JP2020534360A5 (hr) | ||
HRP20240218T1 (hr) | Modulatori integriranog puta stresa | |
HRP20210529T1 (hr) | Inhibitori za mk2 i njihove uporabe | |
HRP20230222T1 (hr) | Modulatori prolijekova integriranog puta stresa | |
WO2015069773A8 (en) | Devices and methods for continuous drug delivery via the mouth | |
HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
TH175340B (th) | อุปกรณ์นวด | |
TH184719B (th) | อุปกรณ์นวด | |
IT201700047632A1 (it) | Composizioni topiche per mantenere e ripristinare l'omeostasi idrica della pelle | |
TH170005B (th) | ฐานสำหรับหน่วยคำนวณและควบคุม | |
TH174143B (th) | เก้าอี้นวด | |
TH174144B (th) | เก้าอี้นวด | |
TH171779B (th) | เก้าอี้นวด | |
TH172888B (th) | อุปกรณ์นวด | |
TH171162B (th) | อุปกรณ์นวด | |
TH172134B (th) | อุปกรณ์นวด | |
TH170092B (th) | เก้าอี้ | |
TH184341B (th) | อุปกรณ์ดูแลผิว | |
JP2019043856A5 (hr) | ||
TH174199B (th) | เครื่องปรับอากาศ | |
TH174790B (th) | เครื่องปรับอากาศ | |
TH174789B (th) | เครื่องปรับอากาศ | |
TH174792B (th) | เครื่องปรับอากาศ |